1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Bioneer Corp

Bioneer Corp

064550.KS
Bioneer CorpKR flagKorea Exchange
34,850.00
KRW
-500.00
- -
899.49BMarket Cap
Bioneer Corp
064550.KS
(Korea Exchange)

Recent

price

34,850.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1,635
1,741.57
1,523.71
1,756.37
1,214.94
1,349.1
1,299.65
1,261.54
1,168.62
1,673.97
8,969.58
8,839.51
8,463.16
10,194.27
11,396.72
12,790.64
13,096
Revenue per Share
-175.8
-430.62
-595.3
-525.53
-922.71
-347.88
-920.85
-539
-428
-361
2,509
1,073
468
-410
-798
-109
-226.16
Basic EPS, GAAP
-7.86
-744.38
-548.25
-503.68
-565.9
-256.04
-532.98
-397.09
-599.86
-477.46
1,688.02
390.68
-376.6
-52.5
-1,049.47
122.83
1,945
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
181.98
Dividend per Share
-1,444.59
-1,499.02
-2,044.98
-2,534
-3,232.48
-3,396.98
-4,436.58
-4,437.53
-4,420.24
-4,525.81
-1,771.71
-599.41
-153.78
-625.33
-1,457.23
-1,605.45
5,514.42
Book Value per Share
2,265.54
1,711.27
1,047.33
876.62
755.77
941.15
378.83
878
1,450.44
1,217.65
6,188.24
8,016.74
9,244.84
8,912.53
8,620.37
8,645.41
8,313.5
Tangible Book Value per Share
12
13
13
14
15
15
17
18
21
22
23
25
26
26
26
26
26
Basic Weighted Avg Shares
20,102
22,765
20,534
23,904
17,854
20,834
21,704
23,268
24,078
36,292
206,987
223,744
218,394
263,237
293,975
330,111
338,012
Sales/Revenue/Turnover
-0.76
-21.26
-21.17
-15.25
-48.4
-17.53
-59.93
-27.2
-48.09
-23.48
51.49
21.04
5.28
0.3
-4.54
4.28
2.72
Operating Margin (%)
4,002
4,224
4,256
4,234
3,312
3,235
3,844
3,903
4,990
5,271
5,375
5,855
8,069
8,953
9,128
8,968
8,862
Depreciation Expense
-2,161
-5,629
-8,022
-7,152
-13,559
-5,372
-15,378
-9,941
-8,818
-7,827
57,899
27,160
12,077
-10,587
-20,584
-2,813
-5,837
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
32.53
- -
- -
- -
82.76
143.45
Effective Tax Rate (%)
-10.75
-24.73
-39.07
-29.92
-75.95
-25.79
-70.85
-42.73
-36.62
-21.57
27.97
12.14
5.53
-4.02
-7
-0.85
-1.73
Profit Margin (%)
14,509
14,313
35
-5,149
-4,316
1,395
-3,014
6,906
6,926
6,995
59,915
85,604
97,848
93,941
82,914
82,750
76,416
Working Capital
10,552
15,955
7,505
1,600
400
650
5,450
5,244
1,840
10,021
7,389
652
8,225
14,357
27,442
61,438
60,697
LT Debt
41,187
37,840
31,423
29,537
30,202
34,531
18,567
27,146
39,037
31,619
147,960
207,592
243,540
234,877
226,891
226,987
218,222
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
16.08
- -
- -
- -
0.77
-1.21
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-372.57
- -
- -
- -
-9.95
-6.29
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
44,500
44,971
46,151
LT Borrowings
60,831
60,142
59,452
LT Finance Leases
1,393
1,297
1,246
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
26
26
26
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
156,485
148,807
150,207
Cash, Cash Equivalents & STI
102,473
92,512
93,251
Accounts Receivable, Net
15,299
12,451
11,820
Inventories
31,039
37,681
39,222
Total Current Liabilities
71,936
66,057
73,791
Payables & Accruals
- -
- -
- -
ST Debt
44,500
44,971
46,151
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
44.34%
10.14%
0.04%
Free Cash Flow
110.99%
285.25%
-111.71%
Net Income, GAAP
-99.96%
-57.64%
-86.33%
Sales/Revenue/Turnover
58.61%
10.04%
12.29%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
79,216
78,444
65,882
70,434
293,975
2025
73,909
88,283
88,065
79,853
330,111
2026
81,810
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-32
-117
-387
- -
-798
2025
-5
-42.76
-38.53
- -
-109
2026
-122.07
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
181.98
- -
- -
- -
- -
Similar Companies
Recursion Pharmaceuticals, Inc. (RXRX)
Lakefront Biotherapeutics (LKFT.AS)
Uni-Bio Science Group Limited (0690.HK)
Beijing Luzhu Biotechnology Co., Ltd. (2480.HK)
Verastem, Inc. (0LOV.L)
Tevogen Bio Holdings Inc. (TVGNW)
Business
Bioneer Corporation (KOSDAQ: 064550), founded in 1992 and headquartered in Daejeon, South Korea, develops and manufactures molecular biology products and molecular diagnostic solutions for life sciences research, clinical diagnostics, and biotechnology applications worldwide, including South Korea, the Americas, Europe, Asia, and Africa. The company offers core products such as PCR and RT-PCR reagents including AccuPower PCR Premix; real-time PCR kits; RNAi tools including siRNA and miRNA; oligonucleotides synthesis services; chemicals, plastic consumables, buffers, and solutions; sample preparation kits and instruments; protein synthesis and purification systems like ExiProgen; gene cloning tools; fluorescence dyes and quenchers; electrophoresis equipment; genome-wide function analysis products; magnetic separation services; molecular diagnostic kits for human, animal, aquatic, plant pathogens, mosquito-borne diseases, food safety, and human pathogens; MDx extraction kits; and instruments for conventional PCR, real-time PCR, automatic nucleic acid extraction, centrifuges, vortex mixers, and electrophoresis. Bioneer operates through segments including genetic research reagents, molecular diagnostics, probiotics via its specialist subsidiary AceBiome—which in late 2025 launches BNR17 Pet Slim Probiotics for pet diets on GS Home Shopping and expanded its AnaParactin brand for joint health—and RNAi new drug development; it maintains production facilities totaling 226,000 square feet in Korea and a U.S. subsidiary in Oakland, California. Recent developments encompass AceBiome's market expansion with probiotic strains like Lactobacillus gasseri BNR17 for weight management and pet applications; ongoing advancements in synthetic biology and siRNA therapeutics through subsidiaries siRNAgen Therapeutics; appointment of external auditor Samil Accounting Corporation for 2025-2027; and Q2 2025 swing to operating profit of 5.6 billion won, reflecting improved financial performance amid revenue of approximately 294 billion won in 2024.